Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

No Increase in HIV Drug Resistance Mutations among Injecting Drug Users on Methadone Maintenance Therapy: A Prospective Cohort Study

Author(s): Chunyuan Huang, Li Ye, Abu S Abdullah, Bingyu Liang, Junjun Jiang, Chuanyi Ning, Ning Zang, Yu Zhang, Yuan Yang, Xi Hu, Quanlue Yang, Chaolian Luo, Feixiang Lao, Huifang Liu, Hao Liang* and Jiegang Huang*

Volume 18, Issue 5, 2020

Page: [362 - 372] Pages: 11

DOI: 10.2174/1570162X18666200712173630

Price: $65

Abstract

Background: Whether HIV-positive injecting drug users (IDUs) are at higher risk of developing drug resistance mutations (DRMs) after methadone maintenance therapy (MMT) than any other HIV-positive population is unclear.

Objective: To compare the incidence of new DRMs in two population groups: antiretroviraltreatment (ART) HIV-positive IDUs and non-drug users.

Methods: A prospective cohort of ART HIV-positive patients including IDUs who received MMT (MMT group) and non-drug users (N-MMT group) was established from April 2016 to December 2017 in Guangxi, China.

Results: Of the 80 participants, 43 were in the MMT group and 37 were in the N-MMT group. Compared with the N-MMT group, the HRs of PIs, NRTIs and NNRTIs for new DRMs in the MMT group was 1.55 (95%CI: 0.28-8.64; P = 0.616), 1.51 (95%CI: 0.44-5.20; P = 0.512) and 0.45 (95%CI: 0.15-1.35; P = 0.155), respectively. There was no dose-response relationship between MMT and new DRMs for PIs, NRTIs and NNRTIs (P > 0.05). The new DRM incidence for NRTIs (138.23 per 104 person-months) was higher than for PIs (94.16 per 104 person-months) and NNRTIs (95.41per 104 person-months) in the MMT group, while the new DRM incidence for NNRTIs (208.24 per 104 person-months) was higher than for PIs (44.13 per 104 person-months) and NRTIs (91.78 per 104 person-months) in the N-MMT group.

Conclusion: Among ART HIV-positive patients, there is no significant difference in the incidence of new DRMs between IDUs receiving MMT and non-drug users. MMT has little impact on the development of DRMs among IDUs.

Keywords: HIV-positive, methadone maintenance therapy, injecting drug users, antiretroviral-treatment, drug resistance mutations, cohort study.

« Previous Next »
Graphical Abstract

[1]
Ray M, Logan R, Sterne JA, et al. HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24(1): 123-37.
[http://dx.doi.org/10.1097/QAD.0b013e3283324283] [PMID: 19770621]
[2]
Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376(9740): 532-9.
[http://dx.doi.org/10.1016/S0140-6736(10)60936-1] [PMID: 20638713]
[3]
Vella S, Schwartländer B, Sow SP, Eholie SP, Murphy RL. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 2012; 26(10): 1231-41.
[http://dx.doi.org/10.1097/QAD.0b013e32835521a3] [PMID: 22706009]
[4]
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14(4): 281-90.
[http://dx.doi.org/10.1016/S1473-3099(13)70692-3] [PMID: 24602844]
[5]
Lessells RJ, Mutevedzi PC, Iwuji CC, Newell ML. Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr 2014; 65(1): e17-24.
[http://dx.doi.org/10.1097/QAI.0b013e31829ceb14] [PMID: 23756374]
[6]
Paydary K, Khaghani P, Emamzadeh-Fard S, Alinaghi SA, Baesi K. The emergence of drug resistant HIV variants and novel anti-retroviral therapy. Asian Pac J Trop Biomed 2013; 3(7): 515-22.
[http://dx.doi.org/10.1016/S2221-1691(13)60106-9] [PMID: 23835806]
[7]
Zuo Z, Liang S, Sun X, et al. Drug Resistance and Virological Failure among HIV-Infected Patients after a Decade of Antiretroviral Treatment Expansion in Eight Provinces of China. PLoS One 2016; 11(12): e0166661
[http://dx.doi.org/10.1371/journal.pone.0166661] [PMID: 27997554]
[8]
World Health Organization. HIV drug resistance report 2017. Geneva: World Health Organization 2017.
[9]
Osman S, Lihana RW, Kibaya RM, et al. Diversity of HIV type 1 and drug resistance mutations among injecting drug users in Kenya. AIDS Res Hum Retroviruses 2013; 29(1): 187-90.
[http://dx.doi.org/10.1089/aid.2012.0182] [PMID: 22856626]
[10]
Zhuang X, Wang Y, Chow EP, Liang Y, Wilson DP, Zhang L. Risk factors associated with HIV/HCV infection among entrants in methadone maintenance treatment clinics in China: a systematic review and meta-analysis. Drug Alcohol Depend 2012; 126(3): 286-95.
[http://dx.doi.org/10.1016/j.drugalcdep.2012.05.028] [PMID: 22726912]
[11]
Sullivan SG, Wu Z. Rapid scale up of harm reduction in China. Int J Drug Policy 2007; 18(2): 118-28.
[http://dx.doi.org/10.1016/j.drugpo.2006.11.014] [PMID: 17689354]
[12]
Hacker MA, Leite I, Friedman SR, Carrijo RG, Bastos FI. Poverty, bridging between injecting drug users and the general population, and “interiorization” may explain the spread of HIV in southern Brazil. Health Place 2009; 15(2): 514-9.
[http://dx.doi.org/10.1016/j.healthplace.2008.09.011] [PMID: 19083260]
[13]
Panda S, Chatterjee A, Bhattacharya SK, et al. Transmission of HIV from injecting drug users to their wives in India. Int J STD AIDS 2000; 11(7): 468-73.
[http://dx.doi.org/10.1258/0956462001916137] [PMID: 10919490]
[14]
Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS 2005; 19(Suppl. 2): S67-72.
[http://dx.doi.org/10.1097/01.aids.0000172879.20628.e1] [PMID: 15930843]
[15]
Maia Teixeira SL, Bastos FI, Hacker MA, Guimarães ML, Morgado MG. Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro. J Med Virol 2006; 78(6): 764-9.
[http://dx.doi.org/10.1002/jmv.20621] [PMID: 16628575]
[16]
Budambula V, Musumba FO, Webale MK, et al. HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users. AIDS Res Ther 2015; 12: 27.
[http://dx.doi.org/10.1186/s12981-015-0070-y] [PMID: 26279669]
[17]
Leng X, Liang S, Ma Y, et al. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China. BMJ Open 2014; 4(10): e005886
[http://dx.doi.org/10.1136/bmjopen-2014-005886] [PMID: 25319999]
[18]
Pham QD, Do NT, Le YN, et al. Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10. J Antimicrob Chemother 2015; 70(3): 941-7.
[http://dx.doi.org/10.1093/jac/dku473] [PMID: 25433009]
[19]
Pando MA, Gómez-Carrillo M, Vignoles M, et al. Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project. AIDS Res Hum Retroviruses 2011; 27(1): 17-23.
[http://dx.doi.org/10.1089/aid.2010.0013] [PMID: 20860532]
[20]
Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14(2): F17-23.
[http://dx.doi.org/10.1097/00002030-200001280-00003] [PMID: 10708278]
[21]
Muyldermans G, Sasse A. HIV-1 resistance and trend analysis in newly diagnosed patients in Belgium. Acta Clin Belg 2014; 69(1): 1-7.
[http://dx.doi.org/10.1179/0001551213Z.0000000001] [PMID: 24635391]
[22]
Kozal MJ, Amico KR, Chiarella J, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004; 18(16): 2185-9.
[http://dx.doi.org/10.1097/00002030-200411050-00011] [PMID: 15577652]
[23]
Kozal MJ, Amico KR, Chiarella J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr 2005; 40(1): 106-9.
[http://dx.doi.org/10.1097/01.qai.0000159666.95455.d2] [PMID: 16123691]
[24]
Kowalski J, Gange SJ, Schneider MF, et al. Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene. J Acquir Immune Defic Syndr 2009; 50(4): 381-9.
[http://dx.doi.org/10.1097/QAI.0b013e318198a619] [PMID: 19214121]
[25]
Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35(1): 46-51.
[http://dx.doi.org/10.1097/00126334-200401010-00006] [PMID: 14707791]
[26]
Chang SY, Chen MY, Lee CN, et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 2008; 61(3): 689-93.
[http://dx.doi.org/10.1093/jac/dkn002] [PMID: 18227088]
[27]
Parczewski M, Leszczyszyn-Pynka M, Witak-Jędra M, et al. Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from Poland differs by transmission category and subtype. J Antimicrob Chemother 2015; 70(1): 233-42.
[http://dx.doi.org/10.1093/jac/dku372] [PMID: 25248322]
[28]
Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189(12): 2174-80.
[http://dx.doi.org/10.1086/420789] [PMID: 15181563]
[29]
Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004; 18(11): 1571-7.
[http://dx.doi.org/10.1097/01.aids.0000131357.52457.33] [PMID: 15238775]
[30]
Paraskevis D, Magiorkinis E, Katsoulidou A, et al. Hellenic Multi-centre study on HIV-resistance. Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 2005; 112(1-2): 115-22.
[http://dx.doi.org/10.1016/j.virusres.2005.03.004] [PMID: 16022906]
[31]
Wood E, Hogg RS, Yip B, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005; 19(11): 1189-95.
[http://dx.doi.org/10.1097/01.aids.0000176219.48484.f1] [PMID: 15990572]
[32]
Chen R, Liang B, Wen B, et al. No Difference in Prevalence of Transmitted Drug Resistance between Injection Drug Users and Non-Injection Drug Users: A Cross-Sectional Study among Antiretroviral Treatment-Naïve HIV Patients. Intervirology 2018; 61(6): 281-91.
[http://dx.doi.org/10.1159/000499367] [PMID: 31018203]
[33]
Zhang G, Yang Y, Ye R, et al. Effect of community-based extension clinics of methadone maintenance therapy for opiate-dependent clients: A prospective cohort study in Dehong Prefecture, Yunnan Province of China. Medicine (Baltimore) 2018; 97(47): e13323
[http://dx.doi.org/10.1097/MD.0000000000013323] [PMID: 30461647]
[34]
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; (3): : CD002209
[http://dx.doi.org/10.1002/14651858.CD002209.pub2] [PMID: 19588333]
[35]
Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, Bailey SP. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis 2011; 30(1): 27-38.
[http://dx.doi.org/10.1080/10550887.2010.531672] [PMID: 21218308]
[36]
Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11(9): 1-171.
[http://dx.doi.org/10.3310/hta11090] [PMID: 17313907]
[37]
Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008; 103(9): 1484-92.
[http://dx.doi.org/10.1111/j.1360-0443.2008.02249.x] [PMID: 18636999]
[38]
Wang Y, Wang H, Li W, et al. Reduced responses to heroin-cue-induced craving in the dorsal striatum: effects of long-term methadone maintenance treatment. Neurosci Lett 2014; 581: 120-4.
[http://dx.doi.org/10.1016/j.neulet.2014.08.026] [PMID: 25157798]
[39]
Nolan S, Hayashi K, Milloy MJ, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend 2015; 156: 57-61.
[http://dx.doi.org/10.1016/j.drugalcdep.2015.08.037] [PMID: 26455554]
[40]
Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; 8: CD004145
[http://dx.doi.org/10.1002/14651858.CD004145.pub4] [PMID: 21833948]
[41]
Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evid Based Med Public Health 2016; 2: 2.
[PMID: 27066590]
[42]
Gossop M, Marsden J, Stewart D, Kidd T. Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up. Addict Behav 2003; 28(4): 785-93.
[http://dx.doi.org/10.1016/S0306-4603(01)00279-9] [PMID: 12726791]
[43]
Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000; 77(3): 331-45.
[http://dx.doi.org/10.1007/BF02386744] [PMID: 10976608]
[44]
Xiaoli W, Lirong W, Xueliang W, Jinsong L, Hengxin L, Wei J. Risk Factors of Hepatitis C Virus Infection in Drug Users From Eleven Methadone Maintenance Treatment Clinics in Xi’an, China. Hepat Mon 2014; 14(11): e19601
[PMID: 25598787]
[45]
Zhao Y, Shi CX, McGoogan JM, Rou K, Zhang F, Wu Z. Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ 2013; 91(2): 93-101.
[http://dx.doi.org/10.2471/BLT.12.108944] [PMID: 23554522]
[46]
Achmad YM, Istiqomah AN, Iskandar S, Wisaksana R, van Crevel R, Hidayat T. Integration of methadone maintenance treatment and HIV care for injecting drug users: a cohort study in Bandung, Indonesia. Acta Med Indones 2009; 41(Suppl. 1): 23-7.
[PMID: 19920294]
[47]
Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010; 105(5): 907-13.
[http://dx.doi.org/10.1111/j.1360-0443.2010.02905.x] [PMID: 20331553]
[48]
Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49(9): 1433-40.
[http://dx.doi.org/10.1086/630209] [PMID: 19807275]
[49]
Socías ME, Wood E, Small W, et al. Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use. Drug Alcohol Depend 2016; 168: 211-8.
[http://dx.doi.org/10.1016/j.drugalcdep.2016.09.013] [PMID: 27701042]
[50]
Reddon H, Milloy MJ, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users. AIDS Behav 2014; 18(4): 740-6.
[http://dx.doi.org/10.1007/s10461-013-0584-z] [PMID: 23918244]
[51]
Bach P, Wood E, Dong H, et al. Association of patterns of methadone use with antiretroviral therapy discontinuation: a prospective cohort study. BMC Infect Dis 2015; 15: 537.
[http://dx.doi.org/10.1186/s12879-015-1255-7] [PMID: 26586238]
[52]
Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84(2): 188-94.
[http://dx.doi.org/10.1016/j.drugalcdep.2006.02.003] [PMID: 16542797]
[53]
Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376(9738): 355-66.
[http://dx.doi.org/10.1016/S0140-6736(10)60832-X] [PMID: 20650513]
[54]
Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012; 31(3): 207-25.
[http://dx.doi.org/10.1080/10550887.2012.694598] [PMID: 22873183]
[55]
Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000; 26(2): 195-205.
[http://dx.doi.org/10.1081/ADA-100100600] [PMID: 10852356]
[56]
Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20(2): 223-31.
[http://dx.doi.org/10.1097/01.aids.0000199825.34241.49] [PMID: 16511415]
[57]
Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008; 22(1): 75-82.
[http://dx.doi.org/10.1097/QAD.0b013e3282f366ff] [PMID: 18090394]
[58]
Wensing AM, Calvez V, Günthard HF, et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med 2016; 24(4): 132-3.
[PMID: 28208121]
[59]
Mathers BM, Degenhardt L, Phillips B, et al. 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372(9651): 1733-45.
[http://dx.doi.org/10.1016/S0140-6736(08)61311-2] [PMID: 18817968]
[60]
Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 2017; 5(12): e1192-207.
[http://dx.doi.org/10.1016/S2214-109X(17)30375-3] [PMID: 29074409]
[61]
Lappalainen L, Nolan S, Dobrer S, et al. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction 2015; 110(8): 1330-9.
[http://dx.doi.org/10.1111/add.12970] [PMID: 25940906]
[62]
Eron JJ Jr, Bosch RJ, Bettendorf D, Petch L, Fiscus S, Frank I. Adult Clinical Trials Group 307 Protocol Team. The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. J Acquir Immune Defic Syndr 2007; 45(2): 249-51.
[http://dx.doi.org/10.1097/QAI.0b013e318050d61f] [PMID: 17527095]
[63]
Carballo-Diéguez A, Sahs J, Goetz R, el Sadr W, Sorell S, Gorman J. The effect of methadone on immunological parameters among HIV-positive and HIV-negative drug users. Am J Drug Alcohol Abuse 1994; 20(3): 317-29.
[http://dx.doi.org/10.3109/00952999409106017] [PMID: 7977217]
[64]
Li Y, Wang X, Tian S, Guo CJ, Douglas SD, Ho WZ. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2002; 185(1): 118-22.
[http://dx.doi.org/10.1086/338011] [PMID: 11756991]
[65]
Bart PA, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001; 23(5): 553-5.
[http://dx.doi.org/10.1097/00007691-200110000-00010] [PMID: 11591903]
[66]
Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000; 24(3): 241-8.
[http://dx.doi.org/10.1097/00042560-200007010-00008] [PMID: 10969348]
[67]
Kharasch ED, Whittington D, Ensign D, et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2012; 91(4): 673-84.
[http://dx.doi.org/10.1038/clpt.2011.276] [PMID: 22398970]
[68]
McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006; 15(1): 23-34.
[http://dx.doi.org/10.1080/10550490500419029] [PMID: 16449090]
[69]
Huruy K, Mulu A, Liebert UG, Maier M. HIV-1C proviral DNA for detection of drug resistance mutations. PLoS One 2018; 13(10): e0205119
[http://dx.doi.org/10.1371/journal.pone.0205119] [PMID: 30286160]
[70]
Derache A, Shin HS, Balamane M, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One 2015; 10(1): e0117430
[http://dx.doi.org/10.1371/journal.pone.0117430] [PMID: 25635815]
[71]
Zaccarelli M, Santoro MM, Armenia D, et al. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. J Clin Virol 2016; 82: 94-100.
[http://dx.doi.org/10.1016/j.jcv.2016.07.007] [PMID: 27472519]
[72]
Lübke N, Di Cristanziano V, Sierra S, et al. Proviral DNA as a Target for HIV-1 Resistance Analysis. Intervirology 2015; 58(3): 184-9.
[http://dx.doi.org/10.1159/000431093] [PMID: 26139571]
[73]
Kabamba-Mukadi B, Duquenne A, Henrivaux P, et al. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med 2010; 11(8): 483-92.
[http://dx.doi.org/10.1111/j.1468-1293.2009.00814.x] [PMID: 20163482]
[74]
Musingwini TV, Zhou DT, Mhandire D, et al. Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans. Open Microbiol J 2017; 11: 45-52.
[http://dx.doi.org/10.2174/1874285801711010045] [PMID: 28553415]
[75]
Gallien S, Charreau I, Nere ML, et al. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. J Antimicrob Chemother 2015; 70(2): 562-5.
[http://dx.doi.org/10.1093/jac/dku395] [PMID: 25344807]
[76]
Alidjinou EK, Coulon P, Hallaert C, et al. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay. J Clin Virol 2019; 121: 104207
[http://dx.doi.org/10.1016/j.jcv.2019.104207] [PMID: 31707202]
[77]
Pessôa R, Sanabani SS. High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors. PLoS One 2017; 12(9): e0185559
[http://dx.doi.org/10.1371/journal.pone.0185559] [PMID: 28953964]

Rights & Permissions Print Cite
Article Metrics
17
© 2024 Bentham Science Publishers | Privacy Policy